These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16808549)

  • 1. Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.
    Callréus T
    Drug Saf; 2006; 29(7):557-66. PubMed ID: 16808549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(62):16827-8. PubMed ID: 15803631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
    Montastruc JL; Sommet A; Lacroix I; Olivier P; Durrieu G; Damase-Michel C; Lapeyre-Mestre M; Bagheri H
    Joint Bone Spine; 2006 Dec; 73(6):629-32. PubMed ID: 17110152
    [No Abstract]   [Full Text] [Related]  

  • 7. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacoepidemiology: an another kind of drug surveillance].
    Pariente A
    Bull Acad Natl Med; 2015; 199(2-3):275-9. PubMed ID: 27476309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of pharmacovigilance: a personal view.
    Edwards IR
    Eur J Clin Pharmacol; 2008 Feb; 64(2):173-81. PubMed ID: 18172624
    [No Abstract]   [Full Text] [Related]  

  • 10. EIDOS: a mechanistic classification of adverse drug effects.
    Ferner RE; Aronson JK
    Drug Saf; 2010 Jan; 33(1):15-23. PubMed ID: 20000863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of Vigimed, a global e-mail system for the exchange of pharmacovigilance information.
    Johansson K; Olsson S; Hellman B; Meyboom RH
    Drug Saf; 2007; 30(10):883-9. PubMed ID: 17867725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European pharmacovigilance: an overview of pharmacovigilance inspections.
    Koster MC; van den Oetelaar AH
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):711-3. PubMed ID: 16142691
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs.
    Lapeyre-Mestre M; Montastruc F
    Therapie; 2019 Apr; 74(2):209-214. PubMed ID: 30792079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigation in field pharmacoepidemiology: a proposal for the actions of pharmacovigilance in Brazil].
    Mota DM
    Rev Bras Epidemiol; 2011 Dec; 14(4):565-79. PubMed ID: 22218656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
    Shakir SA; Layton D
    Drug Saf; 2002; 25(6):467-71. PubMed ID: 12071785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia.
    ; Andersen M; Bergman U; Choi NK; Gerhard T; Huang C; Jalbert J; Kimura M; Kimura T; Kubota K; Lai EC; Ooba N; Park BJ; Pratt N; Roughead EE; Sato T; Setoguchi S; Shin JY; Sundström A; Yang YH
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):700-4. PubMed ID: 23653370
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.
    Bahri P
    Drug Saf; 2010 Dec; 33(12):1065-79. PubMed ID: 21077698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.